Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

计划入组 14 人 · 首次发布于 2013 年 12 月 5 日

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

计划入组 30 人 · 首次发布于 2025 年 2 月 13 日

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

计划入组 31 人 · 首次发布于 2023 年 4 月 18 日

Lutetium-177 DOTA girentuximab

Lutetium Lu-177(Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce))

Lu

Lutetium-177 EVG321

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

Kidney Cancer Research Consortium Advances Novel Combination Therapies Through Multi-Institutional Collaboration

SPLASH Trial: Lutetium-177 Demonstrates Efficacy in Advanced Prostate Cancer

FDA Approves Telix's Pixclara, First FET-PET Imaging Drug for Glioma in the U.S.